Epizyme Current Ratio 2012-2021 | EPZM

Epizyme current ratio from 2012 to 2021. Current ratio can be defined as a liquidity ratio that measures a company's ability to pay short-term obligations.
Epizyme Current Ratio Historical Data
Date Current Assets Current Liabilities Current Ratio
2021-06-30 $0.27B $0.04B 6.66
2021-03-31 $0.34B $0.04B 8.73
2020-12-31 $0.41B $0.04B 9.33
2020-09-30 $0.31B $0.04B 8.95
2020-06-30 $0.36B $0.03B 11.57
2020-03-31 $0.40B $0.03B 14.81
2019-12-31 $0.40B $0.03B 11.61
2019-09-30 $0.32B $0.03B 10.90
2019-06-30 $0.36B $0.03B 10.56
2019-03-31 $0.40B $0.03B 12.55
2018-12-31 $0.27B $0.04B 7.20
2018-09-30 $0.20B $0.03B 7.48
2018-06-30 $0.24B $0.03B 8.09
2018-03-31 $0.26B $0.03B 10.43
2017-12-31 $0.29B $0.03B 11.59
2017-09-30 $0.32B $0.02B 13.69
2017-06-30 $0.20B $0.03B 7.70
2017-03-31 $0.22B $0.02B 10.74
2016-12-31 $0.25B $0.02B 11.50
2016-09-30 $0.28B $0.02B 17.35
2016-06-30 $0.30B $0.02B 18.35
2016-03-31 $0.32B $0.01B 22.79
2015-12-31 $0.21B $0.02B 11.55
2015-09-30 $0.23B $0.02B 13.29
2015-06-30 $0.24B $0.01B 18.13
2015-03-31 $0.25B $0.01B 20.83
2014-12-31 $0.20B $0.02B 11.44
2014-09-30 $0.22B $0.02B 9.13
2014-06-30 $0.24B $0.02B 9.87
2014-03-31 $0.25B $0.03B 10.02
2013-12-31 $0.16B $0.04B 4.62
2013-09-30 $0.14B $0.03B 4.72
2013-06-30 $0.16B $0.03B 4.89
2013-03-31 $0.00B 0.00
2012-12-31 $0.00B 0.00
2012-09-30 $0.00B 0.00
2012-06-30 $0.00B 0.00
2011-12-31 $0.04B $0.01B 3.12
Sector Industry Market Cap Revenue
Medical Medical - Biomedical and Genetics $0.556B $0.016B
Epizyme, Inc. is a biopharmaceutical company. It engages in the discovery, development, planning, and commercialization of therapeutics for cancers. Epizyme, Inc. is headquartered in Cambridge, Massachusetts.
Stock Name Country Market Cap PE Ratio
Bristol Myers Squibb (BMY) United States $133.660B 8.90
Bio-Rad Laboratories (BIO.B) United States $23.483B 50.05
QIAGEN (QGEN) Netherlands $12.482B 21.14
Biohaven Pharmaceutical Holding (BHVN) United States $8.764B 0.00
Emergent Biosolutions (EBS) United States $2.892B 6.98
Arcus Biosciences (RCUS) United States $2.573B 0.00
Myovant Sciences (MYOV) United Kingdom $2.051B 0.00
ADC Therapeutics SA (ADCT) Switzerland $2.021B 0.00
Zymeworks (ZYME) Canada $1.443B 0.00
Ambrx Biopharma (AMAM) United States $0.527B 0.00
SQZ Biotechnologies (SQZ) United States $0.417B 0.00
Enzo Biochem (ENZ) United States $0.172B 50.71